Inhibiting neddylation: A new strategy for tumor therapy
Open Access
- 8 November 2024
- journal article
- review article
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 15 (5) , 101140
Abstract
No abstract availableKeywords
This publication has 149 references indexed in Scilit:
- A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumorsInvestigational New Drugs, 2021
- Gartanin is a novel NEDDylation inhibitor for induction of Skp2 degradation, FBXW2 expression, and autophagyMolecular Carcinogenesis, 2019
- Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumorsInvestigational New Drugs, 2018
- Radiotherapy for Cancer: Present and FutureAdvanced Drug Delivery Reviews, 2017
- A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanomaInvestigational New Drugs, 2016
- ATF4 orchestrates a program of BH3-only protein expression in severe hypoxiaMolecular Biology Reports, 2012
- Posttranscriptional regulation of cancer traits by HuRWIREs RNA, 2010
- The prolyl hydroxylase enzymes that act as oxygen sensors regulating destruction of hypoxia-inducible factor αAdvances in Enzyme Regulation, 2004
- Negative regulators of cytokine signal transductionCellular and Molecular Life Sciences, 1999
- Regulation of the human WEE1Hu CDK tyrosine 15‐kinase during the cell cycle.The EMBO Journal, 1995